Clinical trial
A Phase 2, Single Arm, Open Label Clinical Study to Assess the Safety and Efficacy of YY-20394 in Subjects With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma
NCT04370405 is registered in ClinicalTrials.gov with Shanghai YingLi Pharmaceutical Co. Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Single Arm, Open Label Clinical Study to Assess the Safety and Efficacy of YY-20394 in Subjects With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma
- Lead sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- April 29, 2019
- Completion date
- February 22, 2021
- Enrollment
- 123 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.